Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Says Trodelvy Improved Quality of Life in Breast Cancer in Study

09/16/2021 | 06:20am EDT

By Michael Dabaie

Gilead Sciences Inc. said new data showed its treatment Trodelvy significantly improved quality of life over the standard of care in 2L+ metastatic triple-negative breast cancer.

The company said that in addition to previously reported overall survival benefit observed with Trodelvy compared with chemotherapy, this new subanalysis demonstrated significant and clinically meaningful improvements in health-related quality of life.

Gilead said it presented the results at the European Society of Medical Oncology Congress 2021. TNBC is the most aggressive type of breast cancer and accounts for about 15% of all breast cancers, Gilead said.

"In TNBC, limited treatment options and poor survival outcomes are compounded by a significant decrease in quality of life, especially in relapsed or refractory metastatic disease, where patients can undergo many rounds of chemotherapy," said Sibylle Loibl of the Center for Hematology and Oncology at Bethanien-Hospital Frankfurt. "Trodelvy is not only the first treatment to extend survival in these patients, but this analysis shows it can also significantly lessen the burden of symptoms when quality time is especially important," she said.

Gilead also said new data from the Phase 3 Ascent study in metastatic TNBC showed Trodelvy improved progression-free survival, overall survival and objective response rate compared with chemotherapy in patients who weren't initially diagnosed with TNBC.

"In the metastatic stage of breast cancer, it is not uncommon for people to change from one subtype to another," said Javier Cortes, head of the International Breast Cancer Center in Madrid and Barcelona.

Roughly one-third of patients with TNBC in the study weren't originally diagnosed with TNBC, and still experienced a survival benefit with Trodelvy compared with chemotherapy, Gilead said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

09-16-21 0820ET

All news about GILEAD SCIENCES, INC.
10/15GILEAD SCIENCES : Says Breast Cancer Therapy Receives Positive Opinion by European Medicin..
MT
10/15GILEAD SCIENCES : Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for..
BU
10/15Gilead's Sacituzumab Govitecan Gets Positive CHMP Opinion in Breast Cancer
DJ
10/14GILEAD SCIENCES : to Release Third Quarter 2021 Financial Results on Thursday, October 28,..
BU
10/14VC DAILY : Sprinter Health Collects $33 Million to Join Home-Healthcare Race
DJ
10/13PRESS RELEASE : NanoViricides, Inc. Has Filed its -2-
DJ
10/13PRESS RELEASE : NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program ..
DJ
10/12GILEAD SCIENCES : Morgan Stanley Adjusts Gilead Sciences PT to $84 from $83, Keeps Overwei..
MT
10/11EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation
RE
10/11REGENERON PHARMACEUTICALS : Merck seeks first U.S. authorization for COVID-19 pill
RE
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 25 103 M - -
Net income 2021 6 563 M - -
Net Debt 2021 23 120 M - -
P/E ratio 2021 13,4x
Yield 2021 4,18%
Capitalization 84 795 M 84 795 M -
EV / Sales 2021 4,30x
EV / Sales 2022 4,24x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 67,63 $
Average target price 76,35 $
Spread / Average Target 12,9%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156
BEIGENE, LTD.38.72%33 452